doi: 10.3389/fimmu.2025.1578940 Received 18 February 2025 Accepted 24 March 2025 Published 10 April 2025 Volume 16 - 2025 Edited by Fabrizio Fontana, University of Milan, Italy Reviewed by Bjrn Steen Sklhegg, University of Oslo, Norway Josephine Anthony, Meenakshi Academy of Higher Education and Research, India Updates Copyright 2025 Fang, Gao, Jiang, Li and Li
The GLP-1 pathway: slowing the gut and signaling satiety When retatrutide activates GLP-1 receptors , it triggers the same appetite-reducing effects you see with semaglutide
Global Semaglutide Market Report Scope Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management
Peptides (2006) 27(6):134958
10.1126/science.1255555 Science 45 GrafE
Excess weight puts pressure on the stomach, increasing the risk of reflux